While PSMA is considered one of the foremost biomarkers in prostate cancer with significant overexpression found across the spectrum of disease progression, our work corroborates findings from a recent publication14 indicating that PSMA expression is heterogeneous in lethal mCRPC. The gene discussed is FOLH1; the disease is prostate carcinoma.